CSIMarket


X4 Pharmaceuticals Inc  (NASDAQ: XFOR)
Other Ticker:  
 

X4 Pharmaceuticals Inc

XFOR's Fundamental analysis








Looking into X4 Pharmaceuticals Inc growth rates, revenue grew in the first quarter of 2025 from the same quarter a year ago. Ranking at No. 4

Biotechnology & Pharmaceuticals industry recorded growth of revenues by 11.96 %

X4 Pharmaceuticals Inc realized net income compared to net loss a year ago in first quarter of 2025

More on XFOR's Growth


X4 Pharmaceuticals Inc
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.

X4 Pharmaceuticals Inc PEG ratio is at -0.01 X4 Pharmaceuticals Inc realized cash reduction of $ -88.35 per share in trailing twelve-month period.
Company
0.79
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 0.02.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.2.


More on XFOR's Valuation
 
 Total Debt (Millions $) -
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 729,395
 Net Income/Employee (TTM) $ 339,488
 Receivable Turnover (TTM) 79.45
 Tangible Book Value (Per Share $) -18.43

X4 Pharmaceuticals Inc
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.

X4 Pharmaceuticals Inc PEG ratio is at -0.01 X4 Pharmaceuticals Inc realized cash outflow of $ -88.35per share in trailing twelve-month period.
Company
0.79
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 0.02.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.2.

X4 Pharmaceuticals Inc Price to Book Ratio is at 0.03 lower than Industry Avg. of 1880.05. and higher than S&P 500 Avg. of 0.01

More on XFOR's Valuation

  Market Capitalization (Millions $) 1
  Shares Outstanding (Millions) 0
  Employees 43
  Revenues (TTM) (Millions $) 31
  Net Income (TTM) (Millions $) 15
  Cash Flow (TTM) (Millions $) -20
  Capital Exp. (TTM) (Millions $) -
  Total Debt (Millions $) -
  Dividend TTM ($) 0 $
  Dividend Yield TTM (%) -
  Revenue/Employee (TTM) $ 729,395
  Net Income/Employee(TTM) $ 339,488
  Receivable Turnover Ratio (TTM) 79.45
  Tangible Book Value (Per Share $) -18.43

  Market Capitalization (Millions $) 1
  Shares Outstanding (Millions) 0
  Employees 43
  Revenues (TTM) (Millions $) 31
  Net Income (TTM) (Millions $) 15
  Cash Flow (TTM) (Millions $) -20
  Capital Exp. (TTM) (Millions $) -





  Ratio
   Capital Ratio (MRQ) 3.7
  Total Debt to Equity (MRQ) -
  Tangible Leverage Ratio (MRQ) -
  Asset Turnover Ratio (TTM) 0.19
  Inventory Turnover Ratio (TTM) 2.4





X4 Pharmaceuticals Inc net profit margin of 0.98 % is currently ranking no. 20 in Biotechnology & Pharmaceuticals industry, ranking no. 171 in Healthcare sector and number 2092 in S&P 500.

More on XFOR's Key Ratios





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com